Literature DB >> 33396821

Surgical Treatment of Intrahepatic Cholangiocarcinoma: Current and Emerging Principles.

Eliza W Beal1, Jordan M Cloyd1, Timothy M Pawlik1.   

Abstract

Intrahepatic cholangiocarcinoma (ICC) is a rare, aggressive cancer of the biliary tract. It often presents with locally advanced or metastatic disease, but for patients with early-stage disease, surgical resection with negative margins and portahepatis lymphadenectomy is the standard of care. Recent advancements in ICC include refinement of staging, improvement in liver-directed therapies, clarification of the role of adjuvant therapy based on new randomized controlled trials, and advances in minimally invasive liver surgery. In addition, improvements in neoadjuvant strategies and surgical techniques have enabled expanded surgical indications and reduced surgical morbidity and mortality. However, recurrence rates remain high and more effective systemic therapies are still necessary to improve recurrence-free and overall survival. In this review, we focus on current and emerging surgical principals for the management of ICC including preoperative evaluation, current indications for surgery, strategies for future liver remnant augmentation, technical principles, and the role of neoadjuvant and adjuvant therapies.

Entities:  

Keywords:  biliary tract cancers; intrahepatic cholangiocarcinoma; liver transplantation; surgery

Year:  2020        PMID: 33396821     DOI: 10.3390/jcm10010104

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  3 in total

1.  YY1 and eIF4A3 are mediators of the cell proliferation, migration and invasion in cholangiocarcinoma promoted by circ-ZNF609 by targeting miR-432-5p to regulate LRRC1.

Authors:  Canghai Guan; Lang Liu; Yuqiao Zhao; Xianhe Zhang; Guanglin Liu; Haicun Wang; Xin Gao; Xiangyu Zhong; Xingming Jiang
Journal:  Aging (Albany NY)       Date:  2021-12-13       Impact factor: 5.682

Review 2.  Minimally Invasive Surgery for Intrahepatic Cholangiocarcinoma: Patient Selection and Special Considerations.

Authors:  MacKenzie L Owen; Eliza W Beal
Journal:  Hepat Med       Date:  2021-12-22

3.  The Implications of Treatment Delays in Adjuvant Therapy for Resected Cholangiocarcinoma Patients.

Authors:  Matthew Parsons; Shane Lloyd; Skyler Johnson; Courtney Scaife; Heloisa Soares; Rebecca Kim; Robin Kim; Ignacio Garrido-Laguna; Randa Tao
Journal:  J Gastrointest Cancer       Date:  2022-04-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.